Core Viewpoint - ProPhase Labs Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share, following an initial compliance period that expired on June 24, 2025 [1][2][3] Group 1: Compliance Status - The company was notified by Nasdaq on December 26, 2024, that its common shares had been below the $1.00 bid price for 30 consecutive business days, leading to a compliance period of 180 days [2] - As of the current date, ProPhase has not regained compliance and now has until December 22, 2025, to meet the bid price requirement [3] - To regain compliance, the company's Class A ordinary shares must close at or above $1.00 for at least 10 consecutive business days [3] Group 2: Company Operations - The company plans to monitor its share price and is considering options to regain compliance, asserting that the extension does not impact its business operations or reporting obligations [4] - ProPhase Labs is focused on innovative healthcare solutions, including Whole Genome Sequencing and diagnostic tests, aiming to enhance health and wellness [5]